Compare AMRN & XBIT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AMRN | XBIT |
|---|---|---|
| Founded | 1989 | 2005 |
| Country | Ireland | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Pharmaceuticals and Biotechnology |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 304.7M | 74.4M |
| IPO Year | 1998 | 2015 |
| Metric | AMRN | XBIT |
|---|---|---|
| Price | $14.12 | $2.37 |
| Analyst Decision | Strong Sell | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $12.00 | N/A |
| AVG Volume (30 Days) | ★ 50.3K | 27.1K |
| Earning Date | 04-29-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 55.00 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $181,104,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $1.26 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 39.22 | N/A |
| 52 Week Low | $11.67 | $2.09 |
| 52 Week High | $20.90 | $3.61 |
| Indicator | AMRN | XBIT |
|---|---|---|
| Relative Strength Index (RSI) | 44.79 | 39.06 |
| Support Level | $13.46 | $2.26 |
| Resistance Level | $14.49 | $2.69 |
| Average True Range (ATR) | 0.52 | 0.07 |
| MACD | -0.04 | -0.01 |
| Stochastic Oscillator | 37.86 | 10.34 |
Amarin Corp PLC is a pharmaceutical company. The company is focused on the commercialization and development of therapeutics to improve cardiovascular, or CV, health and reduce CV risk. Its commercialized product includes Vascepa. The company focuses on treatments to stop cardiovascular disease causing death, by providing patients, doctors and investors with reliable cardiovascular treatment options. Geographically, the company derives maximum revenue from United States.
XBiotech Inc is a biopharmaceutical company that discovers and develops True Human monoclonal antibodies derived from human donors to replicate the human immune response in the treatment of various diseases. It has developed a pipeline of product candidates using True Human antibodies targeting both inflammatory and infectious diseases. The company's developement pipeline comprises: Natrunix, an antibody targeting IL-1a in oncology (pancreatic cancer), a clinical stage therapeutic for Methicillin Resistant Staphylococcus aureus (MRSA), and several pre-clinical stage therapeutics, including: an oral delivery antibody therapeutic for colon infection by C. difficile; an injectable therapy for varicella zoster (adult chicken pox), the causative agent for shingles; and an influenza therapy.